Menu

Recreational Cannabis’ Impact on Physicians’ Practice

By Rahim Shah, VP Client Services

August 20, 2018

The Canadian Senate recently passed Bill C-46 which will allow for the legal use of recreational cannabis across Canada by Fall 2018. While some physicians anticipate this new legislation will impact their practices with patients electing to try recreational cannabis instead of more traditional prescription medications or medical cannabis, others anticipate increases in patient visits related to dependence and psychotic symptoms. Take a look at our infographic for insights into Canadian physicians’ perspectives on the legalization of recreational cannabis.

Read More

While 32% of physicians surveyed support legalization, 47% oppose it. Supporting and opposing physicians have differing views on how their practice will be impacted once recreational cannabis is legal.

As a result of increased use of recreational cannabis, opposing GPs are more likely to anticipate an increase in patient visits related to the following conditions: dependence/misuse, effects on the brain, psychotic symptoms, anxiety, fear/panic and depression.

As recreational cannabis becomes easier to obtain, supporting GPs are more likely to anticipate a decline in patient visits related to prescriptions for the following conditions: anxiety/severe stress, chronic pain, fibromyalgia, panic attacks,

Past Quick Polls

COVID-19 Impact on Women in Pharma

The COVID-19 crisis changed the way people work across industries including the pharma industry. MD Analytics teamed up with the professional association for women in the pharma industry Women Leaders in Pharma to conduct a study on the impact on of COVID-19 on women who work in the pharma industry.

read more

Pandemic’s Impact on HCPs Practices and Vaccination Campaign Perceptions

The COVID-19 vaccination campaign is underway in Canada. However, the pandemic has significantly altered HCPs’ practices to date. These changes have impacted workloads, patient assessments, and interactions with pharma. A year into the pandemic, a national COVID-19 vaccination campaign is underway. This begs the question, how are Canadian HCPs doing today? What do they foresee moving forward? Our latest short survey presents the current state of HCPs’ practices in Canada and their assessment of the government’s management of COVID-19.

read more

Remote Detailing for Pharma – Physicians’ perspectives

Our 5-minute online survey conducted in the fall of 2020 sought to gain clarity around remote detailing. This study was conducted with 339 Canadian physicians who are members of the MD Analytics healthcare panel and the results provide actionable recommendations on how to form a more ‘ideal’ pharma remote detail.

read more

We are here to answer your questions.

Share This